Literature DB >> 16286478

A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1/FLT-1.

Rosana D Meyer1, Moosa Mohammadi, Nader Rahimi.   

Abstract

VEGFR-1 is a kinase-defective receptor tyrosine kinase (RTK) and negatively modulates angiogenesis by acting as a decoy receptor. The decoy characteristic of VEGFR-1 is required for normal development and angiogenesis. To date, there is no molecular explanation for this unusual characteristic of VEGFR-1. Here we show that the molecular mechanisms underlying the decoy characteristic of VEGFR-1 is linked to the replacement of a highly conserved amino acid residue in the activation loop. This amino acid is highly conserved among all the type III RTKs and corresponds to aspartic acid, but in VEGFR-1 it is substituted to asparagine. Mutation of asparagine (Asn(1050)) within the activation loop to aspartic acid promoted enhanced ligand-dependent tyrosine autophosphorylation and kinase activation in vivo and in vitro. The mutant VEGFR-1 (Asp(1050)) promoted endothelial cell proliferation but not tubulogenesis. It also displayed an oncogenic phenotype as its expression in fibroblast cells elicited transformation and colony growth. Furthermore, mutation of the invariable aspartic acid to asparagine in VEGFR-2 lowered the autophosphorylation of activation loop tyrosines 1052 and 1057. We propose that the conserved aspartic acid in the activation loop favors the transphosphorylation of the activation loop tyrosines, and its absence renders RTK to a less potent enzyme by disfavoring transphosphorylation of activation loop tyrosines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16286478      PMCID: PMC1360223          DOI: 10.1074/jbc.M506454200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

Review 1.  Receptor tyrosine kinases as targets for anticancer drugs.

Authors:  Esther Zwick; Johannes Bange; Axel Ullrich
Journal:  Trends Mol Med       Date:  2002-01       Impact factor: 11.951

Review 2.  Interaction domains: from simple binding events to complex cellular behavior.

Authors:  Tony Pawson; Monica Raina; Piers Nash
Journal:  FEBS Lett       Date:  2002-02-20       Impact factor: 4.124

Review 3.  The conformational plasticity of protein kinases.

Authors:  Morgan Huse; John Kuriyan
Journal:  Cell       Date:  2002-05-03       Impact factor: 41.582

4.  Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways.

Authors:  H Zeng; H F Dvorak; D Mukhopadhyay
Journal:  J Biol Chem       Date:  2001-05-11       Impact factor: 5.157

5.  Identification of tyrosine residues in vascular endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation.

Authors:  V Dayanir; R D Meyer; K Lashkari; N Rahimi
Journal:  J Biol Chem       Date:  2001-03-08       Impact factor: 5.157

6.  Vascular endothelial growth factor upregulates pigment epithelium-derived factor expression via VEGFR-1 in human retinal pigment epithelial cells.

Authors:  Kyoko Ohno-Matsui; Takeshi Yoshida; Tomoko Uetama; Manabu Mochizuki; Ikuo Morita
Journal:  Biochem Biophys Res Commun       Date:  2003-04-11       Impact factor: 3.575

7.  Recruitment and activation of phospholipase Cgamma1 by vascular endothelial growth factor receptor-2 are required for tubulogenesis and differentiation of endothelial cells.

Authors:  Rosana D Meyer; Catharina Latz; Nader Rahimi
Journal:  J Biol Chem       Date:  2003-02-21       Impact factor: 5.157

8.  VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death.

Authors:  Diether Lambrechts; Erik Storkebaum; Masafumi Morimoto; Jurgen Del-Favero; Frederik Desmet; Stefan L Marklund; Sabine Wyns; Vincent Thijs; Jörgen Andersson; Ingrid van Marion; Ammar Al-Chalabi; Stephanie Bornes; Rhiannon Musson; Valerie Hansen; Lars Beckman; Rolf Adolfsson; Hardev Singh Pall; Hervé Prats; Severine Vermeire; Paul Rutgeerts; Shigehiro Katayama; Takuya Awata; Nigel Leigh; Loïc Lang-Lazdunski; Mieke Dewerchin; Christopher Shaw; Lieve Moons; Robert Vlietinck; Karen E Morrison; Wim Robberecht; Christine Van Broeckhoven; Désiré Collen; Peter M Andersen; Peter Carmeliet
Journal:  Nat Genet       Date:  2003-08       Impact factor: 38.330

9.  Angiogenesis-independent endothelial protection of liver: role of VEGFR-1.

Authors:  Jennifer LeCouter; Dirk R Moritz; Bing Li; Gail Lewis Phillips; Xiao Huan Liang; Hans-Peter Gerber; Kenneth J Hillan; Napoleone Ferrara
Journal:  Science       Date:  2003-02-07       Impact factor: 47.728

10.  The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.

Authors:  Thomas Holbro; Roger R Beerli; Francisca Maurer; Magdalena Koziczak; Carlos F Barbas; Nancy E Hynes
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-09       Impact factor: 11.205

View more
  34 in total

Review 1.  Endothelial cell metabolism in health and disease: impact of hypoxia.

Authors:  Brian W Wong; Elke Marsch; Lucas Treps; Myriam Baes; Peter Carmeliet
Journal:  EMBO J       Date:  2017-06-21       Impact factor: 11.598

2.  A critical role for the E3-ligase activity of c-Cbl in VEGFR-2-mediated PLCgamma1 activation and angiogenesis.

Authors:  Amrik J Singh; Rosana D Meyer; Gyulmagomed Navruzbekov; Rajani Shelke; Lei Duan; Hamid Band; Susan E Leeman; Nader Rahimi
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-19       Impact factor: 11.205

3.  Blood vessel anastomosis is spatially regulated by Flt1 during angiogenesis.

Authors:  Jessica E Nesmith; John C Chappell; Julia G Cluceru; Victoria L Bautch
Journal:  Development       Date:  2017-03-01       Impact factor: 6.868

Review 4.  Targeted therapies for advanced Ewing sarcoma family of tumors.

Authors:  Yunyun Jiang; Joseph Ludwig; Filip Janku
Journal:  Cancer Treat Rev       Date:  2015-03-27       Impact factor: 12.111

Review 5.  Vascular endothelial growth factor in heart failure.

Authors:  Ziad Taimeh; John Loughran; Emma J Birks; Roberto Bolli
Journal:  Nat Rev Cardiol       Date:  2013-07-16       Impact factor: 32.419

6.  Up-regulation of soluble vascular endothelial growth factor receptor-1 prevents angiogenesis in hypertrophied myocardium.

Authors:  Elisabeth Kaza; Klemens Ablasser; Dimitrios Poutias; Eric R Griffiths; Fawzy A Saad; Jochen G Hofstaetter; Pedro J del Nido; Ingeborg Friehs
Journal:  Cardiovasc Res       Date:  2010-10-08       Impact factor: 10.787

7.  Direct contacts between extracellular membrane-proximal domains are required for VEGF receptor activation and cell signaling.

Authors:  Yan Yang; Peng Xie; Yarden Opatowsky; Joseph Schlessinger
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-11       Impact factor: 11.205

8.  Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells.

Authors:  Nader Rahimi; Todd E Golde; Rosana D Meyer
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

Review 9.  Emerging roles of post-translational modifications in signal transduction and angiogenesis.

Authors:  Nader Rahimi; Catherine E Costello
Journal:  Proteomics       Date:  2014-10-08       Impact factor: 3.984

10.  Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2.

Authors:  Kerrington R Molhoek; Heinrich Griesemann; Jianfen Shu; Jeffrey E Gershenwald; David L Brautigan; Craig L Slingluff
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.